These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 19530253)

  • 1. Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
    Bradshaw-Pierce EL; Steinhauer CA; Raben D; Gustafson DL
    Mol Cancer Ther; 2008 Sep; 7(9):3006-17. PubMed ID: 18790781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
    Buck SAJ; Van Hemelryk A; de Ridder C; Stuurman D; Erkens-Schulze S; van 't Geloof S; Teubel WJ; Koolen SLW; Martens-Uzunova ES; van Royen ME; de Wit R; Mathijssen RHJ; van Weerden WM
    Mol Cancer Ther; 2024 May; 23(5):711-720. PubMed ID: 38030379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
    Li Y; Malaeb BS; Li ZZ; Thompson MG; Chen Z; Corey DR; Hsieh JT; Shay JW; Koeneman KS
    Prostate; 2010 May; 70(6):616-29. PubMed ID: 20043297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy.
    Shi Z; Liu M; Zhang X; Wang J; Zhang J; Peng Z; Meng L; Wang R; Guo L; Zhang Q; Li J; Yang L; Liu J; Xu Y; Yan J; Cui J; Ren S; Gao Y; Wang Y; Qi Z
    Theranostics; 2024; 14(9):3565-3582. PubMed ID: 38948069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer.
    Saito Y; Mizokami A; Izumi K; Naito R; Goto M; Nakagawa-Goto K
    Molecules; 2021 May; 26(9):. PubMed ID: 34068627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer.
    Uo T; Ojo KK; Sprenger CCT; Epilepsia KS; Perera BGK; Damodarasamy M; Sun S; Kim S; Hogan HH; Hulverson MA; Choi R; Whitman GR; Barrett LK; Michaels SA; Xu LH; Sun VL; Arnold SLM; Pang HJ; Nguyen MM; Vigil ABG; Kamat V; Sullivan LB; Sweet IR; Vidadala R; Maly DJ; Van Voorhis WC; Plymate SR
    Mol Cancer Ther; 2024 Jul; 23(7):973-994. PubMed ID: 38507737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro.
    Núñez-Iglesias MJ; Novio S; García C; Pérez-Muñuzuri ME; Martínez MC; Santiago JL; Boso S; Gago P; Freire-Garabal M
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.
    Veras ASC; Batista VRG; Correia RR; de Almeida Tavares ME; Rubira RJG; Tavares ER; Giometti IC; Maranhão RC; Teixeira GR
    Sci Rep; 2024 Apr; 14(1):9626. PubMed ID: 38671015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gompertz models with periodical treatment and applications to prostate cancer.
    Schultz L; Gondim A; Ruan S
    Math Biosci Eng; 2024 Feb; 21(3):4104-4116. PubMed ID: 38549320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome.
    Kusebauch U; Campbell DS; Deutsch EW; Chu CS; Spicer DA; Brusniak MY; Slagel J; Sun Z; Stevens J; Grimes B; Shteynberg D; Hoopmann MR; Blattmann P; Ratushny AV; Rinner O; Picotti P; Carapito C; Huang CY; Kapousouz M; Lam H; Tran T; Demir E; Aitchison JD; Sander C; Hood L; Aebersold R; Moritz RL
    Cell; 2016 Jul; 166(3):766-778. PubMed ID: 27453469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
    Wang J; Wei H; Huang Y; Chen D; Zeng G; Lian Y; Huang Y
    Aging (Albany NY); 2019 Aug; 11(15):5769-5785. PubMed ID: 31409760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy.
    Hernandez I; Luna G; Rauch JN; Reis SA; Giroux M; Karch CM; Boctor D; Sibih YE; Storm NJ; Diaz A; Kaushik S; Zekanowski C; Kang AA; Hinman CR; Cerovac V; Guzman E; Zhou H; Haggarty SJ; Goate AM; Fisher SK; Cuervo AM; Kosik KS
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells.
    Wang J; Lian Y; Gu Y; Wang H; Gu L; Huang Y; Zhou L; Huang Y
    Oncotarget; 2017 Dec; 8(62):105047-105060. PubMed ID: 29285232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.
    Lokeshwar VB; Lopez LE; Munoz D; Chi A; Shirodkar SP; Lokeshwar SD; Escudero DO; Dhir N; Altman N
    Cancer Res; 2010 Apr; 70(7):2613-23. PubMed ID: 20332231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serially heterotransplanted human prostate tumours as an experimental model.
    Lopez-Barcons LA
    J Cell Mol Med; 2010 Jun; 14(6B):1385-95. PubMed ID: 19874422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
    Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
    Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
    Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.